Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors

Patients with central and ultra-central lung tumors treated with SABR (50 Gy in 4-5 fractions) experienced few toxicities and good outcomes, similar to patients with peripheral lung tumors.